Quantcast NICE Nixes Lapatinib, Trastuzumab With Aromatase Inhibitors For Some Breast Cancer - Congoo
 
 
CANCER Log In
NICE Nixes Lapatinib, Trastuzumab With Aromatase Inhibitors for Some Breast Cancer
Have an interest in this Story?
Sign Up for Real-Time email updates
Oncology Report  | February 14, 2012

Englandâ??s clinical and cost-effectiveness agency has said that it would not recommend lapatinib or trastuzumab with aromatase inhibitors as first-line treatments for postmenopausal women with HER2 positive metastatic breast cancer. The new negative draft guidance follows previous negative guidance...
Read Full Article   
 
Leave a Comment: You must be logged in to leave a comment     Log in | Register
 

Featured Members
Robert Miller Robert Miller
Member/Manager
Healthcare Industry
Dr. Monte Hessler Dr. Monte Hessler
Chiropractic care for Phoenix, Arizona
Healthcare General

  
  View more profiles

 
Access dozens of premium and subscriptions sites Free! Download now.

Advertise   |   Build a News Circle   |   Get News Briefings   |   Congoo News Home   |   Get the Netpass
About Congoo   |   Terms   |   Privacy   |   Need Help?   |   Site Map
Copyright ©2012 Congoo.com. All Rights Reserved.